RAS is the most frequently mutated oncogene in human cancers, with mutations in about 30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with high sequence homology. K-RAS is the most commonly mutated RAS isoform. The Ras protein is a membrane bound protein with inherent GTPase activity and is activated by numerous extracellular stimuli, cycling between an inactive (GDP-bound) and active (GTP-bound) form[2].In subgroup analyses, KRAS mutation in pancreatic cancer, colorectal cancer, non-small cell lung cancer and ovarian epithelial cancer had HRs of 2.81 (95% CI 1.83-4.30, P<0.01), 1.67 (95% CI 1.25-2.42, P<0.01), 1.64 (95% CI 1.13-2.39, P = 0.01) and 2.17 (95% 1.12-4.21, p = 0.02) for OS, respectively[3].LC-2 induces degradation of endogenous KRASG12C in multiple KRAS mutant cancer cell (NCI-H2030, MIA PaCa-2, SW1573, NCI-H23 and NCI-H358 cells) with DC50s between 0.25 and 0.76 μM. LC-2-induced KRASG12C degradation occurs via a bona fide PROTAC mechanism. MIA PaCa-2, NCI-H23, and SW1573 cells are treated with 2.5 μM of LC-2 for 6, 24, 48, and 72 h. In all three cell lines, maximal KRAS degradation occurred within 24 h and was sustained up to 72 h. LC-2-induced (2.5 μM; 6-24 hours) KRAS G12C degradation modulates Erk signaling in homozygous and heterozygous KRAS mutant cell lines[4]. LC-2 covalently binds KRAS G12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRAS G12C degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRAS G12C cell lines[5].
LC-2 细胞实验
Cell Line
Concentration
Treated Time
Description
References
PR2 cells
400 nM
72 hours
To evaluate the resistance of PR2 cells to ponatinib
Mol Cancer Ther. 2017 Aug;16(8):1623-1633
PR1 cells
660 nM
72 hours
To evaluate the resistance of PR1 cells to ponatinib
Mol Cancer Ther. 2017 Aug;16(8):1623-1633
LC-2/ad cells
25 nM
72 hours
To evaluate the anti-proliferative activity of ponatinib on LC-2/ad cells
Mol Cancer Ther. 2017 Aug;16(8):1623-1633
LC-2/ad cells
6.25-100 µM/mL
4 days
Evaluation of DB07194 inhibitory activity against LC-2/ad cells, showing DB07194 had an IC50 of 12.48 µM, superior to pralsetinib's 23.31 µM.
搜索
